FFA
PCVX icon

Farther Finance Advisors’s Vaxcyte PCVX Stock Holding History

Farther Finance Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1K Sell
399
-159
-28% -$8.64K ﹤0.01% 3870
2026
Q1 		$32.6K Buy
558
+215
+63% +$11.7K ﹤0.01% 3303
2025
Q4 		$15.8K Buy
343
+122
+55% +$5.46K ﹤0.01% 3597
2025
Q3 		$7.96K Buy
221
+85
+63% +$2.82K ﹤0.01% 3543
2025
Q2 		$4.42K Buy
136
+37
+37% +$1.21K ﹤0.01% 3407
2025
Q1 		$3.19K Buy
99
+6
+6% +$480 ﹤0.01% 3222
2024
Q4 		$7.61K Buy
93
+7
+8% +$695 ﹤0.01% 2484
2024
Q3 		$9.83K Buy
86
+9
+12% +$811 ﹤0.01% 2379
2024
Q2 		$5.92K Buy
77
+10
+15% +$681 ﹤0.01% 2323
2024
Q1 		$4.47K Hold
67
– – ﹤0.01% 2122
2023
Q4 		$4.21K Buy
67
+60
+857% +$3.12K ﹤0.01% 2057
2023
Q3 		$357 Buy
7
+5
+250% +$247 ﹤0.01% 2345
2023
Q2 		$100 Buy
+2
New +$95 ﹤0.01% 2426

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Farther Finance Advisors's PCVX Position: Q2 2026 in Review

Farther Finance Advisors reduced its Vaxcyte (PCVX) stake by 28% in Q2 2026, selling an estimated $8.64K and leaving 399 shares worth $23.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3870.

Farther Finance Advisors first reported a position in PCVX in Q2 2023 and has held it in 13 quarters since. The position peaked at $32.6K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Farther Finance Advisors held 399 shares of Vaxcyte worth $23.1K as of Q2 2026.
  • Farther Finance Advisors sold 159 Vaxcyte shares in Q2 2026, an estimated $8.64K.
  • Vaxcyte made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #3870 holding.
  • Farther Finance Advisors first reported a position in Vaxcyte in Q2 2023 and has held it in 13 quarters since.
  • Farther Finance Advisors's Vaxcyte position peaked at $32.6K in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.